---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-22-000019"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:44:19.266911+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Caribou Q3 net loss $26.6M, cash $342.6M; CB-011 IND submitted, CB-010 ODD for FL

## Summary
- Net loss $26.6M vs $21.0M YoY; revenue $3.3M (down from $4.0M) on lower AbbVie collaboration revenue.
- Cash, cash equivalents, and marketable securities $342.6M as of Sept 30, 2022, down from $413.5M at Dec 31, 2021.
- CB-010 ANTLER Phase 1 trial enrolling at dose level 2; ODD for follicular lymphoma granted Sept 2022.
- CB-011 IND for relapsed/refractory multiple myeloma submitted to FDA in Q4 2022; FDA response expected by YE 2022.
- CB-012 IND for r/r AML expected in 2023; CB-020 target selection for CAR-NK solid tumors expected Q4 2022.

## SEC filing metadata
- accession: 0001619856-22-000019
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985622000019/0001619856-22-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985622000019/crbu-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-22-000019
- JSON: https://secwatch.observer/filing/0001619856-22-000019.json
- Plain text: https://secwatch.observer/filing/0001619856-22-000019.txt

## Key facts
- Earnings Releases
  Caribou Biosciences, Inc. reported the third quarter of 2022 results: revenue $3.3 million, net income $26.6 million.
  - Period: the third quarter of 2022
  - Revenue: $3.3 million
  - Net income: $26.6 million
  - Result: reported results
  source text: of September 30, 2022, compared to $413.5 million as of December 31, 2021. Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $3.3 million for the three months ended September 30, 2022, compared to $4.0 million for the same period in 2021. The decrease was primarily due to a decrease in revenue under the AbbVie
  evidence_url: https://www.sec.gov/Archives/edgar/data/1619856/000161985622000019/0001619856-22-000019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.